1. Home
  2. NOMA vs RNTX Comparison

NOMA vs RNTX Comparison

Compare NOMA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOMADAR Corp.

NOMA

NOMADAR Corp.

N/A

Current Price

$2.21

Market Cap

59.1M

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$0.77

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOMA
RNTX
Founded
2023
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.1M
65.3M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
NOMA
RNTX
Price
$2.21
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.0K
413.2K
Earning Date
05-22-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.16
EPS
N/A
N/A
Revenue
$6,376.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$0.69
52 Week High
$10.00
$2.18

Technical Indicators

Market Signals
Indicator
NOMA
RNTX
Relative Strength Index (RSI) 32.34 44.88
Support Level N/A $0.69
Resistance Level $4.63 $1.32
Average True Range (ATR) 0.41 0.07
MACD -0.05 0.01
Stochastic Oscillator 2.11 51.50

Price Performance

Historical Comparison
NOMA
RNTX

About NOMA NOMADAR Corp.

Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: